(Reuters) – The U.S. Food and Drug Administration said on Wednesday it has withdrawn its approval for TG Therapeutics Inc’s lymphatic cancer treatment Ukoniq over safety concerns.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Shounak Dasgupta)
